Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor

New England Journal of Medicine

Volumn 376, Issue 23, 2017, Pages 2300-2302

  Fralick, Michael ^a   Schneeweiss, Sebastian ^a   Patorno, Elisabetta ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT; SYMPTOM; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MIDDLE AGED; RISK;

ADULT; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PROPENSITY SCORE; RISK; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020403719     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1701990     Document Type: Letter

References (5)

1. Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 2013;1:140-51.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
3. FDA Drug Safety Communication. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. May 15, 2015 (https://www.fda.gov/Drugs/DrugSafety/ucm446845.htm).
4. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016;7:135-8.
5. Wang SV, Verpillat P, Rassen JA, Patrick A, Garry EM, Bartels DB. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin Pharmacol Ther 2016;99:325-32.